Small Pharma has announced results from its Phase 2a trial of its intravenous formulation of DMT – SPL026 – demonstrating improvement in depression and anxiety.
Dr Devon Christie, Medical and Therapeutic Services Director with Numinus, speaks to Psychedelic Health about the representation of women in the field of psychedelics – from...
In this article, Nina Patrick, Ph.D.
A new collaboration between Emyria and Australia’s specialist trauma service, the PAX Centre, is aiming to develop a scalable MDMA-assisted therapy model for patients with complex...
Optimi Health has entered into a long-term distribution agreement with Mind Medicine Australia to supply its MDMA formulation, OPTI-MHCL, and GMP psilocybin capsules.
In this article, Nina Patrick, Ph.D.,
PharmAla Biotech Holdings has been named the exclusive supplier of both GMP and engineering MDMA to Awakn LS Europe Holdings Limited.
Using machine learning analysis, researchers have determined that a mystical and insightful psychedelic drug experience may be linked to long-term reductions in anxiety and depression symptoms.
With an increase in psychedelic research and clinical trials, it is becoming increasingly important to train psychedelic therapists.
Awakn Life Sciences has confirmed it has signed its fourth Licensing Partnership agreement in North America with Ken Starr MD Wellness Group, an addiction treatment facility...